Skip to main content

Please note: this event has passed


Speaker:

Dr Hormuzd A Katki, PhDSenior InvestigatorNational Cancer Institute, NIH, USA

Title: 

New quantitative approaches to precision screening: The example of lung-cancer screening

Hormuzd A. Katki received a B.S. in math from the University of Chicago and an M.S. in statistics from Carnegie-Mellon University. He received a Ph.D in biostatistics from Johns Hopkins University in 2006, where he received the Margaret Merrell Award for research by a biostatistics doctoral student. Dr. Katki joined NCI in 1999, became a principal investigator in 2009, and was appointed senior investigator upon receiving NIH scientific tenure in 2015.

Abstract: 

Lung-cancer screening may become the first cancer screening modality in the US where guidelines will recommend using an individualized risk model to decide who is eligible for screening. I will summarize the research that underlies this conclusion, then I will discuss our approaches to 3 key questions that remain. The first question is criteria for deciding on the risk-threshold at which to offer screening. The seemingly obvious answer to that question is a cost-effectiveness analysis, but in the US, costs are generally not allowed to be considered by guidelines bodies. The second question is how to update individual risk with screening test results. I will present a simple Markov model approach that uses screening test results to directly modify pre-screening individualized risk. The third key question is how to account for comorbidities and life-expectancy when selecting people for screening. A risk-based approach will generally choose older people with comorbidities, who may not live long even if their life is saved by screening. I present our individualized model for life-years gained from screening, and compare those chosen for screening by individualized life-years gained versus by individualized risk. In contrast to the current risk-based approach to precision screening, life-years gained is a benefit-based approach that is conceptually the better approach to precision-screening. Throughout the talk, I will discuss where my experience in cervical cancer screening inspired our approaches to these questions.

 

Event details

Seminar Rooms, Innovation Hub, Guy’s Cancer Centre
Innovation Hub
Innovation Hub, Cancer Centre, Great Maze Pond, London SE1 9RT